IL291009A - A novel oncolytic virus platform for cancer treatment with myxoma virus - Google Patents
A novel oncolytic virus platform for cancer treatment with myxoma virusInfo
- Publication number
- IL291009A IL291009A IL291009A IL29100922A IL291009A IL 291009 A IL291009 A IL 291009A IL 291009 A IL291009 A IL 291009A IL 29100922 A IL29100922 A IL 29100922A IL 291009 A IL291009 A IL 291009A
- Authority
- IL
- Israel
- Prior art keywords
- virus
- platform
- treat cancers
- myxoma
- new oncolytic
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894925P | 2019-09-02 | 2019-09-02 | |
| US201962944233P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/049061 WO2021046125A1 (en) | 2019-09-02 | 2020-09-02 | A new oncolytic virus platform to treat cancers with myxoma virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291009A true IL291009A (en) | 2022-05-01 |
Family
ID=74681244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291009A IL291009A (en) | 2019-09-02 | 2022-03-01 | A novel oncolytic virus platform for cancer treatment with myxoma virus |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11117934B2 (https=) |
| EP (1) | EP4025228A4 (https=) |
| JP (1) | JP2022546539A (https=) |
| KR (1) | KR20220112241A (https=) |
| CN (1) | CN114615988A (https=) |
| AU (1) | AU2020342510A1 (https=) |
| CA (1) | CA3152779A1 (https=) |
| IL (1) | IL291009A (https=) |
| MX (1) | MX2022002547A (https=) |
| TW (1) | TW202122411A (https=) |
| WO (1) | WO2021046125A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3106202A1 (en) | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
| WO2020051248A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| MX2022002547A (es) | 2019-09-02 | 2022-05-18 | Univ Arizona State | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. |
| WO2022067038A1 (en) * | 2020-09-25 | 2022-03-31 | President And Fellows Of Harvard College | Immunotherapeutic virus for the treatment of cancer |
| CA3210350A1 (en) * | 2021-03-01 | 2022-09-09 | Leslie Lynne Sharp | Multi-armed myxoma virus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2153284B1 (es) * | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| KR100747646B1 (ko) | 2005-02-25 | 2007-08-08 | 연세대학교 산학협력단 | 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물 |
| WO2007143545A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
| EP2150618B1 (en) | 2007-05-04 | 2017-10-11 | University Health Network | Il-12 immunotherapy for cancer |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| WO2011156273A1 (en) * | 2010-06-06 | 2011-12-15 | Mount Sinai School Of Medicine | Recombinant rna viruses and uses thereof |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| CN104039333B (zh) | 2011-06-09 | 2018-11-16 | 佛罗里达大学研究基金会有限公司 | 移植物抗宿主疾病的治疗或预防方法 |
| CN105829537B (zh) | 2013-11-28 | 2020-09-22 | 巴法里安诺迪克有限公司 | 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 |
| KR20160140075A (ko) | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| CN108025056B (zh) * | 2015-06-19 | 2022-01-14 | 新罗杰股份有限公司 | 用于病毒栓塞的组合物和方法 |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2018027316A1 (en) * | 2016-08-09 | 2018-02-15 | Alkayyal Almohanad | Oncolytic rhabdovirus expressing il12 |
| WO2018156106A1 (en) | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
| CA3106202A1 (en) | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
| KR20210042135A (ko) | 2018-08-08 | 2021-04-16 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 개선된 폭스바이러스 수율을 위한 방법 |
| AU2019321667A1 (en) | 2018-08-16 | 2021-03-04 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
| WO2020051248A1 (en) | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| EP3946373A4 (en) | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| US20220296660A1 (en) | 2019-09-02 | 2022-09-22 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
| MX2022002547A (es) | 2019-09-02 | 2022-05-18 | Univ Arizona State | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. |
| CA3210350A1 (en) | 2021-03-01 | 2022-09-09 | Leslie Lynne Sharp | Multi-armed myxoma virus |
-
2020
- 2020-09-02 MX MX2022002547A patent/MX2022002547A/es unknown
- 2020-09-02 US US17/010,711 patent/US11117934B2/en active Active
- 2020-09-02 WO PCT/US2020/049061 patent/WO2021046125A1/en not_active Ceased
- 2020-09-02 CA CA3152779A patent/CA3152779A1/en active Pending
- 2020-09-02 CN CN202080076788.8A patent/CN114615988A/zh active Pending
- 2020-09-02 JP JP2022514014A patent/JP2022546539A/ja active Pending
- 2020-09-02 TW TW109130086A patent/TW202122411A/zh unknown
- 2020-09-02 KR KR1020227010537A patent/KR20220112241A/ko not_active Ceased
- 2020-09-02 AU AU2020342510A patent/AU2020342510A1/en not_active Abandoned
- 2020-09-02 EP EP20861091.5A patent/EP4025228A4/en active Pending
-
2021
- 2021-06-24 US US17/357,624 patent/US20210324014A1/en not_active Abandoned
-
2022
- 2022-03-01 IL IL291009A patent/IL291009A/en unknown
- 2022-08-22 US US17/893,052 patent/US12331079B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210324014A1 (en) | 2021-10-21 |
| CN114615988A (zh) | 2022-06-10 |
| EP4025228A4 (en) | 2023-09-06 |
| CA3152779A1 (en) | 2021-03-11 |
| US12331079B2 (en) | 2025-06-17 |
| AU2020342510A1 (en) | 2022-03-24 |
| JP2022546539A (ja) | 2022-11-04 |
| US20210061864A1 (en) | 2021-03-04 |
| EP4025228A1 (en) | 2022-07-13 |
| US20230025706A1 (en) | 2023-01-26 |
| TW202122411A (zh) | 2021-06-16 |
| WO2021046125A1 (en) | 2021-03-11 |
| MX2022002547A (es) | 2022-05-18 |
| KR20220112241A (ko) | 2022-08-10 |
| US11117934B2 (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291009A (en) | A novel oncolytic virus platform for cancer treatment with myxoma virus | |
| IL284375A (en) | Replication competent oncolytic group b adenovirus | |
| IL245312B (en) | Recombinant oncolytic herpes simplex virus | |
| IL260480B (en) | Oncolytic virus modifications | |
| IL261554B (en) | Cancer treatment with an oncolytic virus combined with a checkpoint inhibitor | |
| IL250103B (en) | Combination of an oncolytic virus with immune checkpoint modulators | |
| PL3659614T3 (pl) | Onkolityczny wirus krowianki | |
| HUE054799T2 (hu) | VSV/NDV hibrid vírusok onkolitikus viroterápiás alkalmazása | |
| EP3490574B8 (en) | Expression of pten-long with oncolytic viruses | |
| SG11202102272UA (en) | Oncolytic virus platform to treat hematological cancer | |
| IL280854A (en) | Recombinant myxoma viruses and their use | |
| SG10201604654RA (en) | Biomarkers and combination therapies using oncolytic virus and immunomodulation | |
| IL285221A (en) | Use of oncolytic viruses to treat cancer | |
| GB202015255D0 (en) | Synthetic viruses | |
| EP4041256A4 (en) | Oncolytic viruses that express multi-specific immune cell engagers | |
| GB201504251D0 (en) | Oncolytic herpes simplex virus infected cells | |
| GB201814867D0 (en) | Modified Oncolytic Adenoviruses | |
| GB201321144D0 (en) | Improved oncolytic viruses | |
| EP3886847B8 (en) | Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses | |
| SG11202008589TA (en) | Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy | |
| EP3875119A4 (en) | ONCOLYTIC VIRUS FOR CANCER THERAPY | |
| IL258299B (en) | Variant with multiple copies and increased resistance to the virus | |
| SG11202100305SA (en) | Methods of treating cancer with tnf expressing myxoma virus | |
| EP3068411A4 (en) | Oncolytic viruses and increased cancer treatment regimens | |
| IL285312A (en) | Risk stratification in cancers associated with viruses |